ResMed Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RMD research report →
Range $213 – $300
Price Chart
About the company
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service.
- CEO
- Michael J. Farrell
- IPO
- 1995
- Employees
- 11,370
- HQ
- San Diego, CA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend, trading above both the 50-day and 200-day moving averages. It sits well above the 52-week low and below the 52-week high, which points to a recovery phase rather than a breakout extension.
Street sentiment is mixed but constructive: the consensus sits at Hold, while the average target near $264 implies upside from current levels. Recent action has leaned positive, with RBC upgrading to Outperform and Mizuho lifting its target to $270, even as several firms stayed neutral.
Execution has been steady, with eight straight EPS beats and the latest quarter topping estimates by 9.0%. Next-year EPS is modeled at 12.08 versus 10.98 TTM, so shareholders should watch whether margin discipline and demand can keep that glide path intact.
The signal is mostly noise, with the activity dominated by automatic and in-kind transactions rather than clear discretionary conviction. One notable sale by the CEO stands out against a cluster of F and M code filings, so the pattern leans to net selling but not a broad insider exodus.
Profitability remains strong, with a 34.0% operating margin, 27.8% net margin, and 61.8% gross margin. Growth is still healthy at 5.9% revenue growth and 23.2% earnings growth, while free cash flow reached $1.96 billion and the balance sheet shows $643 million in net cash.
ResMed screens as a premium healthcare equipment name with stronger profitability than many med-tech peers, supported by high margins and net cash. The valuation is not cheap, but the market is paying for consistent execution and recurring cash generation.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.14B
- P/E
- 22.04
- Fwd P/E
- 19.41
- PEG
- 1.80
- P/S
- 5.95
- P/B
- 5.83
- EV/EBITDA
- 15.06
- Div Yield
- 1.04%
- Gross Margin
- 61.18%
- Op Margin
- 33.02%
- Net Margin
- 27.79%
- ROE
- 25.14%
- ROIC
- 21.18%
Latest fiscal year · YoY change
- Revenue
- $5.65B+9.9%
- Gross Profit
- $3.45B+13.0%
- Op Income
- $1.89B
- Net Income
- $1.52B+8.8%
- EPS
- $10.47+9.6%
- OCF Growth
- +3.1%
- FCF Growth
- -0.7%
- 52W High
- $277.67
- 52W Low
- $180.27
- 50D MA
- $233.49
- 200D MA
- $223.51
- Beta
- 0.76
- RSI (14)
- 51
- Avg Volume
- 1.31M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ResMed posted a strong Q1 FY2027, with 7% core constant-currency revenue growth, 50 bps gross margin expansion, and continued heavy capital returns, while holding full-year guidance steady.· October 29, 2026
- Q1 revenue was $1.4 billion, up 6% reported and 7% in core constant currency; non-GAAP EPS rose 14% to $2.91.
- Non-GAAP gross margin was 62.5%, up 50 basis points year over year, helped by productivity gains and delayed supply-chain expansion costs.
- Management reiterated FY2027 guidance: core constant-currency revenue growth of 5% to 7%, reported revenue of $5.75 billion to $5.85 billion, and non-GAAP EPS of $12 to $12.25.
- ResMed returned more than $1 billion to shareholders in the quarter, including $936 million of share repurchases, and still expects more than $1.85 billion returned in FY2027.
- Product and ecosystem initiatives remained a major focus, including AirCurve 11 ST/ST-A, the new AirTouch F40 fabric mask, myAir updates, and AI tools like Dawn and Smart Comfort.
ResMed reported Q1 FY2027 total revenue of $1.4 billion, up 6% reported and 7% core constant currency. Non-GAAP EPS was $2.91, up 14% year over year, and non-GAAP gross margin was 62.5%, up 50 basis points. Non-GAAP operating margin was 35.8%, down 30 basis points year over year. Free cash flow was $374 million, and the company ended the quarter with about $1 billion of cash. For FY2027, management reiterated core constant-currency revenue growth of 5% to 7%, reported revenue of $5.75 billion to $5.85 billion, non-GAAP EPS of $12 to $12.25, low-double-digit basis-point gross margin expansion, and a slight increase in operating margin percentage. They also said they still expect more than $1.85 billion returned to shareholders this year, with Q2 expected to be seasonally stronger in revenue but with gross margin slightly down sequentially, R&D roughly flat, and SG&A higher.
Mick Farrell framed the quarter as a strong start to FY2027 and emphasized ResMed’s long-term strategy around innovation, portfolio management, and capital return. He highlighted new products and digital tools as central to building a more connected sleep-health ecosystem, while stressing that awareness, access, and adherence are still the key growth levers. His tone was confident and expansive, especially around U.S. manufacturing, AI-enabled features, and consumer partnerships that he believes can broaden the funnel over time.
Aaron Bloomer said the quarter benefited from solid demand across devices, masks, and the remaining RCS business, plus productivity gains across procurement, manufacturing, and distribution. He noted that gross margin exceeded expectations largely because some supply-chain expansion spending, especially the Indiana build-out, was phased into Q2; he also said inflation, especially on electronic components, should build through the rest of the year. On cash use, he pointed to $374 million of free cash flow, roughly $1 billion of cash on hand, and $936 million of share repurchases in the quarter, while maintaining capex guidance of $160 million to $180 million.
Analysts focused on why gross margin beat expectations, whether pricing would ramp later in the year, and how to think about the second half after a strong Q1. Management said pricing was very modest and had essentially no Q1 benefit, while the bigger margin upside came from timing of Indiana-related supply-chain investments; they also said pricing benefit should build through the year. Questions also covered Rest of World growth, GLP-1/pill-form effects, marketing campaigns, portfolio M&A, U.S. competition, fabric masks, and U.S. manufacturing. Management’s answers were consistent: the marketing and myAir initiatives are still early and not yet making material top-line contributions, GLP-1s appear supportive of the funnel and adherence, tuck-in M&A remains under consideration but nothing is imminent, and the company believes its ecosystem can defend and grow share even if competition increases.
The call showed multiple sources of momentum: device and mask growth, a gross margin upside beat, and continued gains from product innovation and digital engagement. Management sounded confident that pricing, marketing, myAir, new masks, and consumer partnerships can support durable growth, while the balance sheet and cash generation allow substantial shareholder returns.
Management acknowledged that some of the drivers behind the Q1 beat were timing-related and may reverse, including Indiana supply-chain spending and the seasonal unwind in France fleet renewals later in the year. They also said marketing and partnership initiatives are still early and not yet contributing materially, while inflation remains a live headwind and operating leverage may be variable quarter to quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 140.66M
- Float Shares
- 139.80M
of shares held by institutions
923 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RMD, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Kelly MorrisonHouse · MN03 | Sell | Jun 4, 25 | Filing → |
| Kelly MorrisonHouse · MN03 | Sell | Apr 28, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Jan 13, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 15, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | May 3, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Oct 17, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 2, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 31, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 18.88M | ▼ 158.04K |
| Blackrock, Inc. | 11.95M | ▼ 362.95K |
| Vanguard Capital Management LLC | 9.45M | ▼ 28.09K |
| Vanguard Portfolio Management LLC | 7.92M | ▲ 10.14K |
| State Street Corp | 6.52M | ▼ 161.49K |
| Geode Capital Management, LLC | 4.42M | ▲ 67.88K |
| Bank Of New York Mellon Corp | 3.73M | ▼ 468.38K |
| First Trust Advisors LP | 2.69M | ▲ 410.08K |
| Morgan Stanley | 1.91M | ▼ 17.62K |
| Invesco Ltd. | 1.69M | ▼ 369.25K |
| Northern Trust Corp | 1.47M | ▼ 225.84K |
| Nordea Investment Management Ab | 1.46M | ▲ 70.66K |
Held by 1,669 ETFs
Biggest fund positions in RMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | De Witte Jan | sell | 429 |
| Nov 11, 26 | Farrell Michael J. | other | 3,465.749 |
| Nov 11, 26 | Farrell Michael J. | other | 2,209.793 |
| Nov 11, 26 | Farrell Michael J. | other | 2,435.843 |
| Nov 11, 26 | Bloomer Aaron | other | 1,095.137 |
| Nov 11, 26 | FARRELL PETER C | other | 169.142 |
| Nov 11, 26 | De Witte Jan | other | 59.981 |
| Nov 11, 26 | Gill Harjit | other | 35.731 |
| Nov 11, 26 | Rider Michael J | other | 547.469 |
| Nov 11, 26 | Rider Michael J | other | 498.624 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RMD coverage
Recent articles, reports, and earnings notes.

ResMed (RMD): Sleep-Health Growth With Margin Upside
ResMed combines durable sleep-apnea demand, connected digital health, and expanding margins. The report supports a Buy view despite valuation discipline and product-transition risks.

What to Watch as DRC Medicine's SPAC Merger Heads to Close
DRC Medicine is a Tokyo-based healthcare and biotech company going public via a merger with Ribbon Acquisition Corp. (NASDAQ: RIBB). The setup offers a development-stage story with real upside if its mask, diagnostics, and certification pipeline advances, but shareholders should watch redemption risk and dilution closely.

ResMed Inc. (RMD) falls on softer FY27 outlook
ResMed Inc. (RMD) falls after hours as investors react to a softer fiscal 2027 outlook tied to suspended ventilator sales and higher cost pressure. The company still topped Q4 EPS estimates and posted solid full-year revenue growth, but guidance concerns are driving the selloff.
Want a deeper read on RMD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Is This the Right Time to Hold Resmed Stock in Your Portfolio?
zacks.com · Nov 20
2,267 ResMed Inc. $RMD Shares Acquired by Allspring Global Investments Holdings LLC
defenseworld.net · Nov 18
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).
prnewswire.com · Nov 9
ResMed (NYSE:RMD) vs. Terumo (OTCMKTS:TRUMY) Financial Comparison
defenseworld.net · Nov 6
Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain
barrons.com · Nov 5
Top 10 High Growth Dividend Stocks For November 2026
seekingalpha.com · Nov 5
ResMed: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 2
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
zacks.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice